Allergan, Inc.

Akrivista LLC

Allergen, Inc.

Scott M Whitcup

Patrick Michael Hughes

Michael R Robinson

James Nienyuan Chang

Wendy M Blanda

Robert T Lyons

John T Trogden

Larry Allen Wheeler

Thomas C Malone

Orest Olejnik

Joseph S Adorante

George R Ehring

Michael E Garst

James A Burke

David A Weber

Ahmet Tezel

Gurpreet Ahluwalia

Frederick C Beddingfield

Sydney G Edwards

Terrence J Hunt

Peter A Simmons

Roger Kei Aoki

Devin F Welty

Gerald W Devries

Robert M Burk

John E Donello

David Frederick Woodward

Daniel W Gil

Rhett M Schiffman

Lon T Spada

Wha-Bin Im

Wha Bin Im

Mitchell F Brin

Joan-En Chang-Lin

Jeffrey L Edelman

Mark Holoboski

Alazar N Ghebremeskel

Gerald Woodrow DeVries

Guadalupe Ruiz

Patrick M Hughes

Hui Liu

Peter C Baciu

Werhner C Orilla

Gerald W De Vries

Joan-En Lin

John G Walt

Guang L Jiang

Connie M Stucker

Debbie D Mullins

Erik Lippa

Kun Xu

Marianne M Do

Janet Cheetham

A James Burke

Connie Stucker

Debbie Mullins

In preferred embodiments the invention is directed to ocular compositions for the treatment of dry eye, methods for making such compositions, and suites comprising a plurality of different ocular compositions each having a defined composition. In preferred examples, the invention is directed to compositions comprising at least one natural oil, wherein a first member of the suite of compositions is effective in treating dry in in a first patient having a particular set of symptoms and a different second member of the suite of compositions is effective in treating dry in in a second patient having a different set of symptoms. The invention is also directed to methods of making and using the compositions, and to skin care compositions for use around the eye, such as the upper and lower eyelids having a lubricating, non-irritating base composition comprising at least one natural oil.

Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye

In preferred the invention is directed to ocular compositions for the treatment of dry eye, methods for making such compositions, and suites comprising a plurality of different ocular compositions each having a defined composition. In preferred examples, the invention is directed to compositions comprising at least one natural oil, wherein a first member of the suite of compositions is effective in treating dry in in a first patient having a particular set of symptoms and a different second member of the suite of compositions is effective in treating dry in in a second patient having a different set of symptoms. The invention is also directed to methods of making and using the compositions, and to skin care compositions for use around the eye, such as the upper and lower eyelids having a lubricating, non-irritating base composition comprising at least one natural oil.

Anti-angiogenesis compositions, and methods of using such compositions, useful for injection into the vitreous of human eyes are provided. Such compositions include MAAC solutions or particles present in a therapeutically effective amount, a viscosity-inducing component, and an aqueous carrier component. The compositions have viscosities at about 25&#xb0; C. of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity at 25&#xb0; C. is in the range of from about 80,000 cps to about 300,000 cps.

High viscosity macromolecular compositions for treating ocular conditions

Improved dermal filler formulation comprising a hyaluronic acid and a botulinum toxin.

Dermal filler

The present invention is directed to compositions and methods for injection into fat deposits for sustained release of compounds which result in localized fat reduction.

Sustained release bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction

Compositions and methods for treating dry age related macular degeneration (dry AMO) by administration to an intraocular location of an anti-neovascular agent (such as bevacizumab) in either a liquid or solid polymeric vehicle (or both), such as a biodegradable hyaluronic acid or PLGA (or PLA).

Method for treating atrophic age related macular degeneration

Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include small particles of a poorly soluble therapeutic agent that facilitates formation of concentrated regions of the therapeutic agent in the retinal pigmented epithelium of an eye. The particles are formed by combining a therapeutic agent with an ophthalmically acceptable polymer component. The particles have sizes less than about 3000 nanometers, and in some cases, less than about 200 nanometers. One example of a composition includes particles of triamcinolone acetonide and hyaluronic acid have a size less than about 3000 nanometers.

Compositions and methods for localized therapy of the eye

Compositions, and methods of using such compositions, useful for placement, for example injection, into the interior of human or animal eyes are provided. Such compositions include a therapeutic component, such as one or more corticosteroids, a biocompatible polymeric component, and a solvent component. The composition is in a fluid form before placement in the interior of an eye, and becomes less fluid after the composition is placed in the eye to form an extended or delayed release drug delivery element or system. The drug delivery element is formed by the dissipation of the solvent from the composition when the composition is placed in the interior of an eye. One example of a composition includes triamcinolone acetonide as a therapeutic agent. A method of treating an ophthalmic condition, or otherwise improving or enhancing vision of a patient, comprises placing the fluid composition in the interior of the eye. The method may be practiced by injecting the fluid composition into the interior of the eye.

Ophthalmic compositions and methods for treating ophthalmic conditions

Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include corticosteroid component-containing particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 300,000 cps. The compositions advantageously suspend the particles for prolonged periods of time.

Pharmaceutical compositions

Methods for treating and preventing ocular conditions by administering an compound to the vitreous chamber of a patient at risk of, or suffering from, the ocular condition.

Methods for treating retinopathy with extended therapeutic effect

The present invention is directed to compositions and methods for the treatment of post-chemotherapeutic hypotrichosis. More specifically, the present invention is directed to the use of compositions comprising bimatoprost for the treatment of post-chemotherapeutic hypotrichosis which may be applied before, during and after receiving chemotherapeutic treatment.

Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists

Growing community of inventors

Laguna Hills, CA, United States of America

Scott M Whitcup